Status:
RECRUITING
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Shanghai Zhongshan Hospital
Guangzhou Institute of Respiratory Disease
Conditions:
Pulmonary Function
Eligibility:
FEMALE
Brief Summary
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are...
Detailed Description
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are...
Eligibility Criteria
Inclusion Criteria:
- Gender: female.
- Age: no limitation.
- Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient.
Exclusion Criteria:
- Suspected LAM patients without other supporting evidence for LAM diagnosis.
- No diffuse cystic lesions in the lung.
- Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established.
- Without signed informed consent.
- Difficult to follow up.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT03193892
Start Date
January 1 2017
End Date
October 1 2026
Last Update
September 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730